CheckMate 214 Exploratory Biomarker Analysis: Predicting Response to Nivolumab Plus Ipilimumab in Advanced RCC

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Results from CheckMate 914 (Part A): adjuvant nivolumab plus ipilimumab vs placebo in resected stage II/III clear-cell RCC at high risk of recurrence, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Experts highlight key studies being reported at the upcoming 2022 ESMO Congress in this commentary from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Released: September 8, 2022

Expert faculty discuss key updates on treatment options in renal cell carcinoma, from Clinical Care Options (CCO)

Katy Beckermann, MD, PhD Naomi B. Haas, MD Eric Jonasch, MD Released: August 1, 2022